(Q33234917)

English

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874] (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

phase III clinical trial

0 references

0 references

Vanna Chiarion Sileni

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Paola Del Bianco

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gian Luca De Salvo

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Antonella Romanini

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Michele Guida

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Adriano Paccagnella

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maurizio Dalla Palma

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Emanuele Naglieri

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ruggero Ridolfi

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Barbara Silvestri

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maria Michiara

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

0 references

publication date

27 February 2006

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

44

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Update on adjuvant interferon therapy for high-risk melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Duration of survival for disseminated malignant melanoma: results of a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

A case of interferon-alpha-induced pneumonitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1421423

21 June 2018

Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-44

21 January 2018

Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Induced interstitial pneumonitis: role of pegylated interferon alpha 2b]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The calculation of received dose intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16504154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-44

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16504154%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33234917&oldid=2195156662"